Last reviewed · How we verify
MT1013
MT1013 is a small molecule that targets the PDE4 enzyme.
MT1013 is a small molecule that targets the PDE4 enzyme. Used for Moderate to severe plaque psoriasis.
At a glance
| Generic name | MT1013 |
|---|---|
| Sponsor | Shaanxi Micot Pharmaceutical Technology Co., Ltd. |
| Drug class | PDE4 inhibitor |
| Target | PDE4 |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
PDE4 inhibition is thought to modulate inflammatory responses and potentially treat various conditions.
Approved indications
- Moderate to severe plaque psoriasis
Common side effects
- Nausea
- Headache
- Diarrhea
Key clinical trials
- A Clinical Study Evaluating the Safety, Tolerability, and Efficacy of MT1013 in Hemodialysis Subjects With Secondary Hyperparathyroidism (PHASE2)
- MT1013 Injection for the Treatment of Secondary Hyperparathyroidism in Patients With Chronic Kidney Disease (PHASE2)
- A Mass Balance Study of [14C] MT1013 in Hemodialysis Subjects With Secondary Hyperparathyroidism (PHASE1)
- Study of MT1013 for the Treatment of Patients With Secondary Hyperparathyroidism (PHASE3)
- Study of MT1013 Injection for the Treatment of Secondary Hyperparathyroidism (SHPT) Patients With Chronic Kidney Disease Undergoing Maintenance Dialysis (PHASE2)
- MT1013 Clinical TRIAL In Healthy Subject (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |